Merck Group

What Merck Group does

Merck KGaA, Darmstadt, Germany is a publicly listed German science and technology company founded in 1668, operating across three integrated business sectors: Healthcare, Life Science, and Electronics. With over 62,000 employees across 65 countries, the company delivers prescription pharmaceuticals (oncology, neurology and immunology, fertility, endocrinology, and rare tumors), laboratory chemicals and bioprocessing tools under the MilliporeSigma brand, and advanced semiconductor materials, thin films, optronics, formulations, specialty gases, and metrology/inspection under EMD Electronics. In the United States and Canada, the company's subsidiaries operate under the umbrella brand EMD due to trademark rights held by the unrelated Merck & Co., Inc. Notable proprietary technologies include the Intermolecular combinatorial materials innovation platform for semiconductors, a bio-based HPLC solvents portfolio achieving 25.9% CO2e emission reduction versus fossil-fuel-based alternatives, and emerging quantum chemistry software developed through a partnership with HQS Quantum Simulations.

Merck generates revenue through three distinct models aligned to its sectors: prescription-based hospital and clinic sales for healthcare products, e-commerce (Sigma-Aldrich/MilliporeSigma) and direct sales for life science products, and direct enterprise field sales to semiconductor manufacturers for electronics products. Distribution spans direct enterprise field sales teams, an e-commerce storefront reaching long-tail SMB researchers and laboratories, pharmacy and hospital networks, and regional distributors/resellers across global markets. The company invests in proprietary technologies across mRNA, semiconductor materials, and bio-based laboratory solvents, alongside emerging computing areas including quantum chemistry and high-performance computing (a state-of-the-art HPC facility launched in Munich in November 2025 in collaboration with Lenovo and Equinix).

In June 2026, Merck announced an all-cash acquisition of Bio-Techne Corporation for US$11.3 billion (EUR 9.9 billion) at $73 per share to strengthen its position in fast-growing life sciences markets. The company has over CHF 1 billion invested in Western Switzerland with a state-of-the-art biotech development center in Vevey (recognized by the 2025 BioAlps Industry Award), and continues to pursue strategic partnerships including with Tata Electronics for semiconductor materials supply in India (January 2026 MoU for the Dholera fab) and HQS Quantum Simulations for quantum chemistry software development. In 2025, Merck divested its Surface Solutions business (SUSONITY) to Global New Materials International, signaling active portfolio refocus on the three core sectors, and reached a fertility medicine pricing deal with the Trump administration in October 2025 in exchange for US tariff relief.

Name

Merck Group

Legal name

Merck KGaA, Darmstadt, Germany

Website

https://merckgroup.com

Company type

Public

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Merck KGaA is a publicly listed German science and technology company operating across Healthcare, Life Science, and Electronics sectors, serving pharmaceutical, bioprocessing, and semiconductor manufacturing customers globally with over 62,000 employees across 65 countries.

Ownership category

akta.pro rank

Product category

Diversified Pharmaceuticals and Life Sciences

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industry

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)

Keywords

• Pharmaceutical manufacturing
• Life science tools
• Semiconductor materials
• Biopharmaceutical solutions
• Specialty chemicals

Headquarters

HQ city

Darmstadt

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare: Revenue from pharmaceutical products covering oncology, neurology & immunology, fertility, endocrinology, and general medicine. Products include prescription medicines, biologic therapies, and fertility treatments sold to hospitals, clinics, and pharmacies globally through prescription-based sales.
2. Life Science: Revenue from laboratory chemicals, process solutions, and discovery tools for biopharmaceutical production, research institutions, and diagnostics. Includes the Sigma-Aldrich, MilliporeSigma, and EMD Serono brands. Products sold via e-commerce and direct sales to research labs and pharma manufacturers.
3. Electronics: Revenue from semiconductor materials, thin films, specialty gases, optronics, formulations, metrology, inspection, and delivery systems for the electronics and semiconductor industries. Sold directly to chip manufacturers and electronics companies.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Merck Group develops, manufactures, and sells pharmaceutical products (oncology, neurology, immunology, fertility, endocrinology, rare tumors), life science tools and process solutions (Sigma-Aldrich/MilliporeSigma for biopharmaceutical manufacturing and research), and electronic materials (semiconductor thin films, specialty gases, optronics, metrology). Products are sold globally to hospitals, biopharmaceutical manufacturers, research institutions, and semiconductor fabricators through direct enterprise sales, e-commerce, and distributor networks across 65 countries.

Product overview

Merck Group operates as a diversified science and technology company organized into three interconnected business sectors: Life Science (Process Solutions, Advanced Solutions, Discovery Solutions), Healthcare (Oncology, Neurology & Immunology, Fertility, General Medicine covering cardiovascular/metabolism/endocrinology, and Rare Tumors), and Electronics (Thin Films, Optronics, Formulations, Metrology and Inspection, Delivery Systems & Services, Specialty Gases, and Intermolecular®). The company provides tools, services, and expertise across pharmaceutical research, drug development, manufacturing quality control, and advanced materials for semiconductor and electronics applications. Recent product launches include a bio-based solvents portfolio for HPLC launched in May 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Process Solutions: Life Science process solutions for biopharmaceutical manufacturing, including filtration, purification, and chromatography technologies.
• Advanced Solutions
• Discovery Solutions
• Intermolecular

Products and services

• Process Solutions Life Science process solutions providing tools, services and expertise for biopharmaceutical production and manufacturing workflows, serving biopharmaceutical manufacturers globally.
• Advanced Solutions Life Science advanced solutions supporting complex bioprocessing and specialized manufacturing requirements for drug substance and product manufacturing.
• Discovery Solutions Life Science discovery solutions providing tools and services including antibodies, proteins, assays, and cell biology products for research, drug discovery and early development.
• Oncology Pharmaceuticals Healthcare therapeutic area focused on cancer treatment through innovative prescription medicines and biologic therapies, sold to hospitals, clinics, and pharmacies globally.
• Neurology & Immunology Pharmaceuticals Healthcare therapeutic area addressing neurological disorders (e.g., multiple sclerosis) and immunological/autoimmune diseases through prescription medicines and biologic therapies.
• Fertility Treatments Healthcare therapeutic area focused on fertility treatments, IVF medicines, and reproductive health solutions distributed through hospitals and pharmacies.
• General Medicine Pharmaceuticals Healthcare therapeutic area covering cardiovascular, metabolism and endocrinology prescription medicines for general medicine applications.
• Rare Tumors Therapies Healthcare therapeutic area focused on rare oncological conditions, providing targeted therapies for rare tumor types.
• Thin Films Materials Electronics technology area providing thin film materials for semiconductor and display manufacturing applications, sold to chip manufacturers and electronics companies.
• Optronics Materials Electronics technology area covering optical and photonic materials and components for photonics and lighting industries.
• Specialty Chemical Formulations Electronics technology area providing specialty chemical formulations for semiconductor manufacturing processes.
• Metrology and Inspection Solutions Electronics technology area providing measurement and inspection solutions for quality control in semiconductor manufacturing.
• Delivery Systems & Services (DS&S) Electronics technology area providing delivery systems and associated services for specialty gases and chemicals in semiconductor manufacturing.
• Specialty Gases Electronics technology area providing specialty gases for semiconductor and electronics manufacturing applications.
• Intermolecular® Custom Innovation Acquired semiconductor materials innovation company providing custom thin film, coating solutions, and combinatorial methods with high-throughput experimentation for developing new materials used in chip manufacturing.
• Bio-Based Solvents for HPLC Bio-based solvent portfolio for high-performance liquid chromatography using renewable feedstocks as direct replacements for acetonitrile, methanol and ethanol, achieving 25.9% average reduction in CO2e emissions while maintaining analytical precision and drop-in compatibility with existing HPLC systems.

Quantifiable outcome

• 25.9% reduction in CO₂e emissions achieved by Merck's bio-based HPLC solvents compared to conventional fossil-fuel-based chromatography solvents, while maintaining analytical precision and drop-in compatibility with existing HPLC systems.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• HQS Quantum SimulationscoreStrategic or Co-development Partner · 25 February 2026Merck Group entered a three-year partnership with HQS Quantum Simulations, a startup specializing in quantum chemistry applications for near-term quantum computers, to develop software for quantum chemical research. The collaboration was awarded through Merck's Anniversary Research Grant in Digitalization and Computing as part of their 350th anniversary. The partnership addresses the exponential scaling limitations that prevent classical computers from solving real-world quantum chemistry problems relevant to drug discovery and materials science.
• Tata ElectronicscoreStrategic or Co-development Partner · 9 January 2026Merck signed a memorandum of understanding with Tata Electronics to supply products and services for Tata's upcoming semiconductor fabrication unit in Dholera, Gujarat, India. This partnership supports India's semiconductor self-reliance goals and represents Merck's strategic engagement in India's growing chip ecosystem. CEO Belén Garijo expressed long-term confidence in India's growth potential, with more such deals reportedly in the pipeline.
• Bio-Techne CorporationcoreStrategic or Co-development Partner · 25 June 2025Merck KGaA, Darmstadt, Germany agreed to acquire Bio-Techne Corporation in an all-cash deal at US$73 per share, representing an enterprise value of US$11.3 billion (EUR 9.9 billion). The acquisition aims to strengthen Merck's leadership position in fast-growing life sciences markets.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Shin-Etsu Chemical: Leading Japanese semiconductor materials and silicon wafer producer and a global incumbent in chipmaking materials—comparable to Merck's Electronics segment in specialty gases, photoresists, and advanced semiconductor materials supplied to fabs.
• Novartis: European-headquartered pharmaceutical major with relevant overlap in neurology (MS franchise), oncology, and immunology therapeutic areas—comparable in scale, geography, and therapeutic mix to Merck's Healthcare sector.
• Roche: Swiss-headquartered pharmaceutical and diagnostics major with overlapping presence in oncology, neurology, immunology, and fertility-adjacent therapeutic areas, plus a major diagnostics business that parallels Merck's life science tools franchise. A broad incumbent across multiple Merck verticals.
• Sanofi: European pharmaceutical major with strong immunology (Dupixent), rare disease, and vaccines portfolios overlapping Merck's Healthcare franchises in neurology & immunology, fertility, and rare tumors. Comparable European-listed pharma peer with similar regulatory and reimbursement exposure.

Direct peers

• Bio-Rad Laboratories: Life science research and clinical diagnostics company with comparable product lines in reagents, antibodies, and separation technologies—overlapping Merck's Discovery Solutions and MilliporeSigma research tools businesses.
• Thermo Fisher Scientific: Global leader in life science tools, biopharma services, and laboratory consumables—directly comparable to Merck's Life Science sector (Process Solutions, Advanced Solutions, Discovery Solutions/MilliporeSigma). Both serve research labs, biotech manufacturers, and pharma companies with similar product portfolios and recurring-revenue models.
• Entegris: Specialty materials and equipment supplier to semiconductor manufacturers—directly comparable to Merck's Electronics segment across thin films, specialty gases, formulations, and delivery systems for chip fabrication.
• Danaher: Diversified life sciences and diagnostics platform (Cytiva, Beckman Coulter, Leica, Pall) operating bioprocess solutions, diagnostics, and lab instruments. Highly comparable to Merck's Process Solutions and Advanced Solutions franchises and to the Bio-Techne acquisition rationale.
• Agilent Technologies: Life sciences and applied markets company providing analytical instruments, consumables, and services for pharma, biotech, and diagnostics—directly comparable to Merck's MilliporeSigma discovery and chromatography workflows and laboratory chemicals portfolio.
• Bio-Techne: Pure-play life science tools company specializing in proteins, antibodies, assays, and diagnostic reagents—directly comparable to Merck's Discovery Solutions business and the explicit acquisition target underpinning the Bio-Techne deal.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/emdgroup
• Facebookfacebook.com/emdgroup
• LinkedInlinkedin.com/company/merck-group
• Instagraminstagram.com/_emdgroup_/?hl=en

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merck Group